Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 416

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1A
Chunk 416
---
 have freedom to operate to develop and commercialize Telomir-1.

21

We
may not be able to adequately protect our product candidates or our proprietary technology in the marketplace.

Our
success will depend, in part, on our ability to obtain patents, protect our trade secrets and operate without infringing on the proprietary
rights of others. We may rely upon a combination of patents, trade secret protection (i.e., know-how), trademarks, licenses, and confidentiality
agreements to protect the intellectual property of our product candidates. The strengths of patents in the pharmaceutical field involve
complex legal and scientific questions and can be uncertain. Where appropriate, we seek patent protection for certain aspects of our
products and technology. However, patent protection for naturally occurring compounds is exceedingly difficult to obtain, defend and
enforce. Filing, prosecuting and defending patents throughout the world would be prohibitively expensive, so our policy is to look to
patent technologies with commercial potential in jurisdictions with significant commercial opportunities. However, patent protection
may not be available for some of the products or technology we are developing. If we must spend significant time and money protecting,
defending, or enforcing our patents, designing around patents held by others or licensing, potentially for large fees, patents or other
proprietary rights held by others, our business, results of operations and financial condition may be harmed. We may not develop additional
proprietary products that are patentable.

The
patent positions of pharmaceutical products are complex and uncertain. Although we have sought and expect to continue to seek patent
protection for our product candidates, their methods of use, and methods of manufacture, any, or all of them may not be subject to effective
patent protection. If any of our products are approved and marketed for an indication for which we do not have an issued patent, our
ability to use our patents to prevent a competitor from commercializing a non-branded version of our commercial products for that non-patented
indication could be significantly impaired or even eliminated.

Publication
of information related to our product candidates by us, or others may prevent us from obtaining or enforcing patents relating to these
products and product candidates. Furthermore, others may independently develop similar products, may duplicate our products, or may design
around our patent rights. In addition, any of our issued patents may be opposed and/or declared invalid or unenforceable. If we fail
to adequately protect our intellectual property, we may face competition from companies who attempt to create a generic product